Skip to main content
Figure 4 | Orphanet Journal of Rare Diseases

Figure 4

From: Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)

Figure 4

Spleen volume over time by PAb status and genotype group. A) Spleen volume over time by PAb status at the landmark point. There are no statistically significant differences at any time point. B) Spleen volume over time by genotype group. Week 0, FS/SSM vs MS, p = 0.007. Week 18, FS/SSM vs MS, p = 0.007. Week 36, FS/SSM vs MS, p = 0.002. Week 53, FS/SSM vs MS, p = 0.002. Week 53, CD/LR vs FS/SSM, p = 0.034. CD/LR, complete deletion/large rearrangement; FS/SSM, frameshift/splice site mutation; MS, missense mutation; PAb+, persistently antibody positive; PAb−, persistently antibody negative.

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172